title: [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
abstract: OBJECTIVE
  We investigated the effectiveness, safety and plasma concentration of long-acting carteolol hydrochloride 2% ophthalmic solution (LA) as compared with the original carteolol hydrochloride 2% ophthalmic solution(CA).
  
  
  METHODS
  Patients with primary open angle glaucoma and ocular hypertension were randomized to 62 patients of LA group (LA once a day) and 62 patients of CA group (CA twice a day) in this multicenter, open-label trial. The intraocular pressure (IOP), pulse rate, blood pressure and plasma concentration were examined for 8 weeks.
  
  
  RESULTS
  The IOP reduction and reduction rate were not significant at any point between the two groups. Systolic blood pressure decreased significantly in both groups, however, diastolic blood pressure decreased only in the CA group. The plasma concentration of the LA group was significantly lower than that of the CA group.
  
  
  CONCLUSIONS
  The IOP reduction effect of the LA group was the same as the CA group. This study suggests that long-acting treatment with alginic acid can be useful for reducing systemic side effects.
authors.affiliation: Department of Ophthalmology, Gifu University School of Medicine, 1-1 Yanagido, Gifu-shi, Gifu-ken 501-1194, Japan. mekawase@gifu-u.ac.jp
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Kawase
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Junji
authors.initials: J
authors.lastname: Ono
authors.forename: Toru
authors.initials: T
authors.lastname: Nakajima
authors.forename: Atsuko
authors.initials: A
authors.lastname: Matsuhisa
authors.forename: Torao
authors.initials: T
authors.lastname: Sugiura
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Migita
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ishikawa
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002354:Carteolol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011674:Pulse
chemical_list: D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D002354:Carteolol